Amvuttra approved for expanded use in rare heart disease
The U.S. Food and Drug Administration (FDA) on Thursday approved Alnylam Pharmaceuticals’ Amvuttra/Vutrisiran to treat a rare and fatal heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM).
The injectable drug Amvuttra is approved to treat adults with ATTR-CM, in which defective transthyretin proteins build up in the heart, potentially causing heart failure.
Amvuttra was first approved in 2022 to treat nerve damage associated with ATTR-CM.
Unlike Pfizer’s Vindacl and BridgeBio’s Attruby, which stabilize the production of the transthyretin protein, Amvutra reduces the production of the disease-causing protein at its source.
Analysts expect the drug to generate nearly $5 billion in sales by 2029, according to data from the London Stock Exchange Group (LSEG).
